Alejandro is a Global Principal Scientist at Lonza with a focus on Upstream Process Development. Alejandro has over 15 years of experience in Biopharma working in R&D and commercial areas, where he has supported the development of a wide range of products (e.g., complex recombinant proteins, AAV and cell-based therapies) and led efforts for smart biomanufacturing.
Alejandro holds a BEng in biotechnology from the IPN, Mexico, and a PhD in chemical and biological engineering from the University of Sheffield, UK.
The biopharmaceutical landscape is rapidly evolving, with an increasing number of novel protein formats advancing toward clinical trials. These newer modalities present unique CMC challenges that demand tailored, agile and data-driven approaches. Strategic partnerships with experienced CDMOs are key maintaining speed and quality in this dynamic environment.
This presentation showcases Lonza's integrated DNA-to-IND and DNA-to-tox programs, designed to streamline and de-risk biologics development. Through real-world case studies, we will explore how leveraging Design of Experiments (DoE) across the development cycle enables faster data-driven decisions, robust process design, and deeper product understanding.
By leveraging decades of expertise and cutting-edge technologies, Lonza can unlock new opportunities for innovators to confidently advance their next-generation biologics to the clinic and, ultimately, to patients.